Abstract
3,3′-Diindolylmethane (DIM) is a promising anticancer agent derived from Brassica vegetables, but the mechanisms of DIM action are largely unknown. We have shown that DIM can upregulate the expression and stimulate the secretion of interferon-gamma (IFNγ) in the human MCF-7 breast cancer cell line. This novel effect may provide important clues to explain the anticancer effects of DIM because it is well known that IFNγ plays an important role in preventing the development of primary and transplanted tumors. Utilizing promoter deletions, we show here that the region between −108 and −36 bp in the IFNγ promoter, which contains two conserved and essential regulatory elements, is required for DIM-induced IFNγ expression. DIM activates both JNK and p38 pathways, induces the phosphorylation of c-Jun and ATF-2, and increases the binding of the homodimer or heterodimer of c-Jun/ATF-2 to the proximal AP-1·CREB-ATF-binding element. Moreover, studies with specific enzyme inhibitors showed that up-stream Ca2+-dependent kinase(s) is required for the inducing effects of DIM in MCF-7 cells. These results establish that DIM-induced IFNγ expression in human breast tumor cells is mediated by activation of both JNK and p38 pathways, which is ultimately dependent on intracellular calcium signaling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- DIM:
-
3,3′-diindolylmethane
- I3C:
-
indole-3-carbinol
- IFNγ:
-
interferon-gamma
- DMSO:
-
dimethylbenzanthracene
- PMA:
-
phorbol 12-myristate 13-acetate
- CsA:
-
cyclosporin A
- CN:
-
calcineurin
- BAPTA:
-
1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetra(acetoxymethyl) ester
- MAPK:
-
mitogen-activated protein kinase
- ERK:
-
extracellular signal-regulated kinase
- JNK:
-
c-Jun N-terminal kinase
- PKC:
-
protein kinase C
- PKA:
-
protein kinase A
- CAT:
-
chloramphenicol acetyltransferase
- EMSA:
-
electrophoretic mobility shift assay
- Sp1:
-
promoter-specific transcription factor 1
- Sp3:
-
promoter-specific transcription factor 3
- ER:
-
endoplasmic reticulum
References
Abate C, Luk D and Curran T . (1991). Mol. Cell. Biol., 11, 3624–3632.
Abdelhafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL and Hoeffler JP . (1992). Mol. Endocrinol., 6, 2079–2089.
Alsayed Y, Uddin S, Mahmud N, Lekmine F, Kalvakolanu DV, Minucci S, Bokoch G and Platanias LC . (2001). J. Biol. Chem., 276, 4012–4019.
Auborn KJ . (2002). Antiviral Ther., 7, 1–9.
Awasthi N and Wagner BJ . (2004). Invest. Ophthalmol. Vis. Sci., 45, 222–229.
Benjamin D, Hartmann DP, Bazar LS and Jacobson RJ . (1986). Am. J. Hematol., 22, 169–177.
Burchert A, Cai D, Hofbauer LC, Samuelsson MKR, Slater EP, Duyster J, Ritter M, Hochhaus A, Muller R, Eilers M, Schmidt M and Neubauer A . (2004). Blood, 103, 3480–3489.
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams B, Sen GC, Silverman RH and Borden EC . (2003). Apoptosis, 8, 237–249.
Chen I, McDougal A, Wang F and Safe S . (1998). Carcinogenesis, 19, 1631–1639.
Chrivia JC, Wedrychowicz T, Young HA and Hardy KJ . (1990). J. Exp. Med., 172, 661–664.
Cippitelli M, Sica A, Viggiano V, Ye JP, Ghosh P, Birrer MJ and Young HA . (1995). J. Biol. Chem., 270, 12548–12556.
Clipstone NA and Crabtree GR . (1992). Nature, 357, 695–697.
Crabtree GR and Clipstone NA . (1994). Annu. Rev. Biochem., 63, 1045–1083.
Cram EJ, Liu BD, Bjeldanes LF and Firestone GL . (2001). J. Biol. Chem., 276, 22332–22340.
Csiszar A, Nagy G, Gergely P, Pozsonyi T and Pocsik E . (2000). Clin. Exp. Immunol., 122, 464–470.
Cui XJ, Zhang P, Deng WL, Oesterreich S, Lu YL, Mills GB and Lee AV . (2003). Mol. Endocrinol., 17, 575–588.
Dalton DK, Pittsmeek S, Keshav S, Figari IS, Bradley A and Stewart TA . (1993). Science, 259, 1739–1742.
de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH and Williams BRG . (2001). J. Leukocyte Biol., 69, 912–920.
Dighe AS, Richards E, Old LJ and Schreiber RD . (1994). Immunity, 1, 447–456.
Dimarzio P, Puddu P, Conti L, Belardelli F and Gessani S . (1994). J. Exp. Med., 179, 1731–1736.
Farrar MA and Schreiber RD . (1993). Annu. Rev. Immunol., 11, 571–611.
Firestone GL and Bjeldanes LF . (2003). J. Nutr., 133, 2448S–2455S.
Garcia-Fernandez MO, Schally AV, Varga JL, Groot K and Busto R . (2003). Breast Cancer Res. Treat., 77, 15–26.
Ge XK, Yannai S, Rennert G, Gruener N and Fares FA . (1996). Biochem. Biophys. Res. Commun., 228, 153–158.
Gentz R, Rauscher FJ, Abate C and Curran T . (1989). Science, 243, 1695–1699.
Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, Dragnev KH, Kelloff GJ and Lubet RL . (1995). Anticancer Res., 15, 709–716.
Hong C, Firestone GL and Bjeldanes LF . (2002a). Biochem. Pharmac., 63, 1085–1097.
Hong CB, Kim HA, Firestone GL and Bjeldanes LF . (2002b). Carcinogenesis, 23, 1297–1305.
Horsley V and Pavlath GK . (2002). J. Cell Biol., 156, 771–774.
Ikeda H, Old LJ and Schreiber RD . (2002). Cytokine Growth Factor Rev., 13, 95–109.
Isakov N and Altman A . (2002). Annu. Rev. Immunol., 20, 761–794.
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ and Schreiber RD . (1998). Proc. Natl. Acad. Sci. USA, 95, 7556–7561.
Kasahara T, Djeu JY, Dougherty SF and Oppenheim JJ . (1983a). J. Immunol., 131, 2379–2385.
Kasahara T, Hooks JJ, Dougherty SF and Oppenheim JJ . (1983b). J. Immunol., 130, 1784–1789.
Kerppola TK and Curran T . (1993). Mol. Cell. Biol., 13, 5479–5489.
Kiang JG, Gist ID and Tsokos GC . (1999). Mol. Cell. Biochem., 199, 179–188.
Laird PW and Jaenisch R . (1994). Human Mol. Genet., 3, 1487–1495.
Lazennec G, Thomas JA and Katzenellenbogen BS . (2001). J. Steroid Biochem. Mol. Biol., 77, 193–203.
McCaffrey PG, Perrino BA, Soderling TR and Rao A . (1993). J. Biol. Chem., 268, 3747–3752.
Mueller H, Liu R, David F and Eppenberger U . (1997). Biol. Chem., 378, 1023–1029.
Nachshon-Kedmi M, Yannai S and Fares FA . (2004). Br. J. Cancer, 91, 1358–1363.
Nachshon-Kedmi M, Yannai S, Haj A and Fares FA . (2003). Food Chem. Toxicol., 41, 745–752.
Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA and Yuan JY . (2000). Nature, 403, 98–103.
Ogretmen B and Safa AR . (1996). Int. J. Cancer, 67, 608–614.
Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR and Kiefer MC . (1997). J. Biol. Chem., 272, 16351–16357.
Pang YB, Norihisa Y, Benjamin D, Kantor RRS and Young HA . (1992). Blood, 80, 724–732.
Penix L, Weaver WM, Pang Y, Young HA and Wilson CB . (1993). J. Exp. Med., 178, 1483–1496.
Penix LA, Sweetser MT, Weaver WM, Hoeffler JP, Kerppola TK and Wilson CB . (1996). J. Biol. Chem., 271, 31964–31972.
Rady PL, Cadet P, Bui TK, Tyring SK, Baron S, Stanton GJ and Hughes TK . (1995). Cytokine, 7, 793–798.
Riby JE, Chang GHF, Firestone GL and Bjeldanes LF . (2000). Biochem. Pharmacol., 60, 167–177.
Rosfjord EC, Maemura M, Johnson MD, Torri JA, Akiyama SK, Woods VL and Dickson RB . (1999). Exp. Cell Res., 248, 260–271.
Ruiz-Ruiz C, Munoz-Pinedo C and Lopez-Rivas A . (2000). Cancer Res., 60, 5673–5680.
Sun SS, Han J, Ralph WM, Chandrasekaran A, Liu K, Auborn KJ and Carter TH . (2004). Cell Stress Chaperones, 9, 76–87.
Walton KM, Rehfuss RP, Chrivia JC, Lochner JE and Goodman RH . (1992). Mol. Endocrinol., 6, 647–655.
Wattenberg LW and Loub WD . (1978). Cancer Res., 38, 1410–1413.
Wiatrak BJ . (2003). Curr. Opin. Otolaryngol. Head Neck Surg., 11, 433–441.
Ye JP, Cippitelli M, Dorman L, Ortaldo JR and Young HA . (1996). Mol. Cell. Biol., 16, 4744–4753.
Yin F, Bruemmer D, Blaschke F, Hsueh WA, Law RE and Van Herle AJ . (2004). Oncogene, 23, 4614–4623.
Young HA and Ghosh P . (1997). Prog. Nucleic Acid Res. Mol. Biol., 56, 109–127.
Acknowledgements
We are grateful to Dr Christopher B Wilson for generously providing the constructs, pIFN-538, pIFN-339, pIFN-108, and plasmids, ATF-2FL, ATF-2BR, wild-type c-Jun, and c-JunΔBR. We are particularly indebted to Dr Howard A Young for kindly providing the plasmids 3 × (−66/−47)CAT, 3 × (−96/−75)CAT, (−108 to −36)CAT, and (−108 to −36)ΔΔ′CAT. We also thank Dr Richard H Goodman for providing the plasmids wild-type CREB and dominant-negative kCREB. This work was supported by the Department of Defense, Army Breast Cancer Research Program Grant DAMDI7-96-1-6149 (BC990908), and by Grants CA69056 and CA102360 from the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xue, L., Firestone, G. & Bjeldanes, L. DIM stimulates IFNγ gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24, 2343–2353 (2005). https://doi.org/10.1038/sj.onc.1208434
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208434
Keywords
This article is cited by
-
Unlocking Diversity: From Simple to Cutting-Edge Synthetic Methodologies of Bis(indolyl)methanes
Topics in Current Chemistry (2024)
-
First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
EPMA Journal (2016)
-
IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells
Cellular Oncology (2016)
-
3,3′-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation
Molecular and Cellular Biochemistry (2011)
-
Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways
Oncogene (2010)